Issues
-
Cover Image
Cover Image
In CD133-positive tumor-propagating cells from glioblastoma, an intact actin cytoskeleton is required for elevated PLK1 activity, which in turn controls mitotic entry and cell polarity. Taken together, the data suggest a Plk1-driven polarity checkpoint, distinguishing CD133-positive tumor-propagating cells from autologous CD133-negative cells. Elevated PLK1 activity protects CD133-positive tumor-propagating cells from BRAF/MAPK inhibition and sensitizes them to Plk1 inhibition. Using immunocytochemistry, it was found that CD133 failed to localize to the membrane and in a polarized fashion in cells treated with actin polymerization inhibitor Latrunculin A. For details, see article by Lerner and colleagues on page 5355. - PDF Icon PDF LinkTable of Contents
Cancer Research
Table of Contents
Breaking Advances
Reviews
Resource
A Federated Network for Translational Cancer Research Using Clinical Data and Biospecimens
Perspective
Essential Components of Cancer Education
Meeting Report
Priority Reports
SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex
Genomic Profiling of Penile Squamous Cell Carcinoma Reveals New Opportunities for Targeted Therapy
UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas
Microenvironment and Immunology
TNF Receptor-2 Facilitates an Immunosuppressive Microenvironment in the Liver to Promote the Colonization and Growth of Hepatic Metastases
Molecular and Cellular Pathobiology
Therapeutics, Targets, and Chemical Biology
miR-124 and Androgen Receptor Signaling Inhibitors Repress Prostate Cancer Growth by Downregulating Androgen Receptor Splice Variants, EZH2, and Src
SLC46A3 Is Required to Transport Catabolites of Noncleavable Antibody Maytansine Conjugates from the Lysosome to the Cytoplasm
Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations
Tumor and Stem Cell Biology
Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells
Disseminated Tumor Cells Persist in the Bone Marrow of Breast Cancer Patients through Sustained Activation of the Unfolded Protein Response
Letters to the Editor
Correction
Acknowledgment to Reviewers
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.